NCT05862259 A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
| NCT ID | NCT05862259 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xinqiao Hospital of Chongqing |
| Condition | Malignant Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2023-08-10 |
| Primary Completion | 2025-08-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2023-08-10 with a primary completion date of 2025-08-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy
Eligibility Criteria
Inclusion Criteria: 1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent. 2. the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology. 3. the stage IV according to the eighth edition of IASLC. 4. PS 0-2, the expected survival \> 3 months. 5. the age of 18-75 years. 6. no contraindication to treatment with immune checkpoint inhibitors. Exclusion Criteria: 1. the patients' compliance was poor, which violated the rules of the trial; 2. the patients with severe dysfunction of vital organs (heart, liver and kidney) ; 3. the patients with other malignant tumors; 4. the researchers considered that the patients should not participate in other conditions of the trial.
Frequently Asked Questions
Who can join the NCT05862259 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Malignant Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05862259 currently recruiting?
Yes, NCT05862259 is actively recruiting participants. Visit ClinicalTrials.gov or contact Xinqiao Hospital of Chongqing to inquire about joining.
Where is the NCT05862259 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT05862259 clinical trial?
NCT05862259 is sponsored by Xinqiao Hospital of Chongqing. The trial plans to enroll 120 participants.